Engineering human brain microphysiological systems for alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) modeling and drug testing: translational promise, limitations, and future directions
Advanced Drug Delivery Reviews · 2026-12 · 239 · 115982
DOI: 10.1016/j.addr.2026.115982 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-12. Verfasst von Yeoheung Yun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological and Bio Engineering, FIT BEST Laboratory, NERVE Center, North Carolina Agricultural and Technical State University…. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain, Chronic Traumatic Encephalopathy. Die Arbeit nennt 259 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation for the National Institutes of Health, National Science Foundation, Cure Alzheimer's Fund.
Themen: Demenz
Abstract (Originalsprache)
This review examines the emerging role of human brain microphysiological systems (HBMPS) in recapitulating diseases and evaluating their translational potential and limitations for Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). Both disorders differ in underlying cause, but converge on shared downstream pathophysiology such as tau pathology, neuroinflammation, and blood-brain barrier (BBB) dysfunction. We review the critical pathophysiological features relevant to modeling AD and CTE and introduce HBMPS platforms/validation strategies as potential tools for evaluating therapeutic compounds as well as drug-delivery approaches. We also provide a systematic comparison of the relative advantages and disadvantages of 2D, HBMPS, Xenograft, and animal models and discuss the future potential of HBMPS's drug-testing platform. We further discuss current challenges of HBMPS related to drug testing, engineering extracellular matrix for tissue chips, and BBB penetration in AD and CTE. We suggest future integration of organoid xenografts and AI-assisted frameworks to enhance pathophysiological fidelity/drug predictive capability and to bridge the gap between HBMPS and animal models. In summary, this paper reviews HBMPS technologies as future translation platforms' direction for drug screening and delivery, while providing current limitations and challenges including model validation, reproducibility, and standardized regulatory bases required for preclinical success for HBMPS use. Rather than comparing biological complexity with translational validity, this review applies a decision-oriented framework that distinguishes mechanistic fidelity, comparative candidate ranking, predictive validation, investigational new drug (IND)-supporting use, and replacement of a defined animal test. For each use, we identify quantitative transport, exposure-response, pharmacodynamic, safety, and reproducibility evidence required to support an advance, redesign, or go/stop decision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical, Biological and Bio Engineering, FIT BEST Laboratory, NERVE Center, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA. Electronic address: yyun@ncat.edu.
- Department of Chemical, Biological and Bio Engineering, FIT BEST Laboratory, NERVE Center, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA.
- Department of Chemical, Biological and Bio Engineering, FIT BEST Laboratory, NERVE Center, North Carolina Agricultural and Technical State University, Greensboro, NC 27411, USA; Department of Biology, NERVE Center, Nort…
- Genetics and Aging Research Unit, Mass General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA.
- Department of Neurology, Washington University in St. Louis, St. Louis, MO 63110, USA.
- UNC Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, UNC at Chapel Hill, 4205 Marsico Hall. 125 Mason Farm Road, Chapel Hill, NC 27599, USA.
Förderung
- Foundation for the National Institutes of Health
- National Science Foundation
- Cure Alzheimer's Fund
Zitieren
APA
Yun, Y., Jena, S., Egido-Betancourt, H., C Uzoechi, S., Kim, D. Y., Lee, J. M., & Nguyen, J. (2026). Engineering human brain microphysiological systems for alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) modeling and drug testing: translational promise, limitations, and future directions. Advanced Drug Delivery Reviews, 239, 115982. https://doi.org/10.1016/j.addr.2026.115982
Vancouver
Yun Y, Jena S, Egido-Betancourt H, C Uzoechi S, Kim DY, Lee JM, et al. Engineering human brain microphysiological systems for alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) modeling and drug testing: translational promise, limitations, and future directions. Advanced Drug Delivery Reviews. 2026;239:115982. doi:10.1016/j.addr.2026.115982
BibTeX
@article{Yun2026,
author = {Yun, Yeoheung and Jena, Satarupa and Egido-Betancourt, Hailey and C Uzoechi, Samuel and Kim, Doo Yeon and Lee, Jin-Moo and Nguyen, Juliane},
title = {Engineering human brain microphysiological systems for alzheimer’s disease (AD) and chronic traumatic encephalopathy (CTE) modeling and drug testing: translational promise, limitations, and future directions},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {239},
pages = {115982},
doi = {10.1016/j.addr.2026.115982}
}
EUVIMED